Yu-Jung Chen (@yujungche) profile picture

cancer biologist (brain) studying macrophages now. #geissmannlab #mskcc views are my own.

Joined May 2018
Photo by Yu-Jung Chen (@yujungche)Photo by Yu-Jung Chen (@yujungche)Photo by Yu-Jung Chen (@yujungche)Photo by Yu-Jung Chen (@yujungche)Photo by Yu-Jung Chen (@yujungche)Photo by Yu-Jung Chen (@yujungche)Photo by Yu-Jung Chen (@yujungche)Photo by Yu-Jung Chen (@yujungche)
I’m excited to share our latest study in @nature on this novel compound called Gliocidin, that targets glioblastoma (#GBM), the most malignant brain tumor. #drugdiscovery #cancer #cancermetabolism @GSKGradSchool @MSKCancerCenter nature.com/articles/s41586-0…
16
80
11
415
47,066
A prime example of how academia should handle data mishandling: transparency, accountability, correction = academic integrity.
For those who read our group’s Cas13 lncRNA study last year, we wanted to share an update: The corrected version of the study is now published in Cell Genomics.
3
130
Proud of this paper from our lab by Tomi Lazarov. In this study, Tomi et al discovered a progenitor population as early as E6.5 that gives rise to tissue resident macrophage and endothelial cells. Congrats to this amazing achievement! #macrophage #ipsc
Our paper is out today in Science Immunology. We describe mesodermal progenitors that give rise to rostral blood vessels, pro-definitive hematopoiesis, and postnatal tissue macrophages, but not primitive or definitive hematopoiesis. doi.org/10.1126/sciimmunol.a…
2
120
Yu-Jung Chen retweeted
Published yesterday (Feb 27, 2025), a groundbreaking case study by Georgiana Long et al. may redefine GBM immunotherapy. The team reports the first known instance of upfront neoadjuvant administration of immune checkpoint inhibitors (a-PD-1 + a-CTLA-4 + a-LAG3) before surgery in GBM, demonstrating robust anti-tumor immune activation and extending survival well beyond the typical prognosis for MGMT-unmethylated GBM. After a single neoadjuvant triplet dose and maximal safe resection, the 56-year-old patient remains recurrence-free for 17 months. These findings have led to a planned first-line neoadjuvant immunotherapy trial (NCT06816927) in newly diagnosed GBM. If confirmed in larger cohorts, this approach could radically change clinical practice, offering renewed hope for patients battling one of the deadliest cancers.
9
40
6
180
49,164
Amazing work and breakthrough in the field of ecDNA cancer biology. This is a work I greatly admired as it is paradigm shifting in modeling tumors that fits the real world picture. Congratulations on this amazing work @aventura71 !
3
363
So happy to see this work out! A little of a comcamaraderie feel with @Xueqian_Zhuang as we are right next to each other's lab, presented our work together in symposium and finalized our manuscript in Nature at around the same time. I love this work and congrats @TuomasTammela!
2
3
385
Yu-Jung Chen retweeted
So excited to share our new paper out in @Nature led by the fabulous @AnaisElewaut and @guillemxtivill providing mechanistic insights into anti-tumor immunity and why it may fail in so many patients! Sky-torial on @obenaufa.bsky.social rdcu.be/d1F7s
#Immunotherapy has transformed #cancer treatment, but some cancers evade immune defenses, causing resistance. @obenaufa's lab has discovered how inflammatory monocytes—a type of immune cell—can reactivate cancer-killing T cells within tumors. Read more: imp.ac.at/news/article/a-tur…
7
19
3
69
7,356
New Night Science Podcast episode! Michael Fischbach talks about choosing a research problem, managing risks, and turning crises into opportunities; as discussed in his Cell paper "Problem choice and decision trees in science and engineering" @mfgrp buzzsprout.com/1744020/episo…
1
9
23
4,464
Yu-Jung Chen retweeted
Saying ‘I don’t know’ in talks has become a lost art, unfortunately. Super interesting discussions require us to be open about what we don’t know and what still needs to be explored. Here’s my recipe for answering questions in talks:
1
38
2
235
26,378
Huge congratulations on the new release, @yujungche and team! ☺️ Check it out in @nature: go.nature.com/3V8Hsjt 📰 Read the PR: bit.ly/3Z5lkYm
I’m excited to share our latest study in @nature on this novel compound called Gliocidin, that targets glioblastoma (#GBM), the most malignant brain tumor. #drugdiscovery #cancer #cancermetabolism @GSKGradSchool @MSKCancerCenter nature.com/articles/s41586-0…
2
9
773
and a special thanks to @bensahralab for this nicely written commentary on our Gliocidin study! I have benefited so much from purine studies that came out from @bensahralab @Gerta_Hoxhaj @AlexValvezan while finding the target of Gliocidin. Forever grateful!
1
8
712